All the Drug Class Drugs
Antineoplastic, Engineered Autologous T Cell Immunotherapy product. idecabtagene vicleucel 260 - 500 x 10^6. For autologous use only. Tmt. consists of a sgle dose for inf. containing a dispersion of CAR-pos. viable T cells in one or more bags. The target dose is 420 x 106 CAR-pos. viable T cells within a range of 260 to 500 x 106 CAR-pos. viable T cells.
For adults with relapsed and refractory multiple myeloma who have received at least two prior ther., incl. an immunomodulatory agent, a proteasome inhib. and an anti-CD38 antibody and have demonstr. dis. progress. on the last ther.
C/I: Hypersens.
Antineoplastic. Fluorouracil 50 mg / 1 g. CREAM: 20 g. Pre-malignant cond:
Apply thinly to affect. area 1-2 x dly.
Malignant cond: Apply 1-2 x dly under
occlusive dressing where practical.
Should not harm healthy skin. Cont.
tmt. until marked inflamm. resp. from
treated area. Alleviate severe
discomfort with steroid cream. Usual
tmt. 3-4 wks or longer. Healing may
take up to 1-2 months after stopping
ther. Use in child not recommend.
C/I: Hypersens., pregn., lact. co-admin
antiviral nucleoside drugs.
Anti-Androgen, Antineoplastic. Apalutamide 60 mg, 240 mg. F.C. TABS.: 120. 240 mg (four 60 mg or 1 240 mg tabs). admin. orally once dly. Swallow the tabs. whole. The drug can be taken with / without food. Pts. should also receive a gonadotropin-releasing hormone (GnRH) analog concur. or should have had a bilater. orchiectomy.
Dose Modific.: If a pt. experiences a greater than or equal to Grade 3 toxic. or an intoler. side effect, hold dosing until sympt. improve to less than or equal to Grade 1 or original grade, then resume at the same dose or a reduced dose (180 mg or 120 mg), if warranted.
Tmt. of pts. with non-metast., castrat.-resist. prostate cancer (NM-CRPC).
C/I: Hypersens.
Antineoplastic. Fluorouracil 50 mg/ 1 gr. Antimetabolite (purine analog) fluorouracil 5% w/w
Alum. tube, Cr. dermal use , 20 g.
To be applied 1 or 2 / d in pre-malign., w/o occlusive dressing. In malign., 1 or 2 / d under an occlusive dressing where practicable. Tmt. to be contin. until there is marked inflammatory resp. from treated area, prefer. with some erosion in the case of pre-malignant condit. The usual duration of treatment for an initial course of ther. is 3-4 weeks.
| Healing may not be complete until 1-2 mo. after ther. is stopped. See prescript. details. |
Antineoplast. to treat actinic keratosis multipl. and superf. basal cell carcinoma in adlts.
C/I: Hypersens., pregn., breastfeed., conc. use with antiviral nucleosides.
Antineoplastic. eribulin 0.44 mg/ml. VIAL. Sol. for IV inj. 1/6 X 2 ml (0.88 mg eribulin)
Ready to use sol.: 1.23 mg/m2 to be admin. intrav. over 2 to 5 min on Days 1 and 8 of every 21-day cycle.
Tmt. of adlt pts with locally adv. or metast. breast cancer who have progressed after at least one chemotherap. regimen for adv. dis. Prior ther. should have incl. an anthracycline and a taxane in either the adj. or metast. setting unless pts were not suitable for these tmts. For the tmt of adlt pts with unresectable liposarcoma who have received prior anthracycline cont. ther. (unless unsuitable) for adv. or metast. dis..
C/I: Hypersens. Breastfeed.
Antineoplastic. hydroxycarbamide 500 mg. Caps. 100 X 500 mg
Doses are based on real or ideal BW, whichever is the less.
In CML initial dose is 40 mg/kg/d depend. on the white cell count. The dose is reduced by 50 % (20 mg/kg/d when the white cell count has dropped below 20 x 109/l. Dose is then adjusted indiv. to keep the white cell count at 5 – 10 x 109/l. Dose should be reduc. if white cell counts fall below 5 x 109/l, and incr. if white cell counts > 10 x 109/l are observed.
If the white cell count falls below 2.5 x 109/l, or the platelet count below 100 x 109/l, ther. to be interrupted until the count rises significant. towards normal.
Trial period for determining effect is six weeks. If there is signif. clinical resp., ther. may be continued indef.
In essential thrombocythaemia, starting dose is 15 mg/kg/d with dose adjustm. to maintain a platelet count below 600 x 109/l without lowering the white blood cell count below 4 x 109/l.
In polycythaemia vera, start at dose of 15 – 20 mg/kg/d. The dose should be adjust. indiv. to maintain the haematocrit below 45 % and platelet count below 400 x 109/l. In most pts this can be achieved with doses of 500 to 1,000 mg/d.
If haematocrit and platelet count can be sufficiently controlled., ther. may be continued indef.
Tmt of pts with chronic myeloid leukaemia (CML) in the chron. or acceler. phase of the dis.
Tmt of pts with essential thrombocytaemia or polycythaemia vera with a high risk for thromboembolic complicat.
C/I: Hypersens. Sev. bone marrow depression, leukocytopenia (< 2.5 x 109 leukocytes/l), thrombocytopenia (< 100 x 109 platelets/l) or sev. anaemia.
